Medicare Part D coverage · vancomycin · RxCUI 2000133
vancomycin 25 MG/ML Oral Solution [Firvanq]
Per the CMS 2026 Part D formulary file, vancomycin 25 MG/ML Oral Solution [Firvanq] is covered by 29 Medicare Part D plans (0.6% of enrollable products), averaging Tier 2.6, with prior authorization required on 0% of covering formularies.
- 0.6%
- Plan coverage
- 29
- Plans covering
- T2.6
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for vancomycin 25 MG/ML Oral Solution [Firvanq]
Per the CMS 2026 Part D formulary file, vancomycin 25 MG/ML Oral Solution [Firvanq] (RxNorm concept RXCUI 2000133, generic name vancomycin) appears on 5 distinct formulary files spanning 29 Medicare Part D plan offerings - 0.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 3, with a cross-plan average of Tier 2.6.
Real-world access to vancomycin 25 MG/ML Oral Solution [Firvanq] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 40% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 161,077 Part D beneficiaries filled vancomycin 25 MG/ML Oral Solution [Firvanq] in 2023, with total plan-and-beneficiary spending of $66,162,664 and an average per-beneficiary annual cost of $410.75. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry vancomycin 25 MG/ML Oral Solution [Firvanq] today.
Coverage Details
- Formularies covering
- 5
- Plans covering
- 29
- Coverage rate
- 0.6%
- Tier range
- Tier 1 – Tier 3
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 40% of formularies
2023 Medicare Spending
- Beneficiaries
- 161,077
- Total spending
- $66,162,664
- Avg per beneficiary
- $410.75
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering vancomycin 25 MG/ML Oral Solution [Firvanq]
29 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 9 plans
| Presbyterian Dual Plus (HMO D-SNP) | Presbyterian Health Plan | T3 | No | $0 | NM |
| Presbyterian Senior Care Extra Health Plan with Rx (HMO) | Presbyterian Health Plan | T3 | No | $0 | NM |
| Óptimo Plus (PPO) | Triple S Advantage, Inc. | T3 | No | $0 | PR |
| Contigo Plus (HMO C-SNP) | Triple S Advantage, Inc. | T3 | No | $0 | PR |
| Brillante (HMO-POS) | Triple S Advantage, Inc. | T3 | No | $0 | PR |
| Enlace Plus (HMO) | Triple S Advantage, Inc. | T3 | No | $0 | PR |
| ContigoEnMente (HMO C-SNP) | Triple S Advantage, Inc. | T3 | No | $0 | PR |
| Ahorro Plus (HMO) | Triple S Advantage, Inc. | T3 | No | $0 | PR |
| Presbyterian Senior Care Plan 3 with Rx (HMO) | Presbyterian Health Plan | T3 | No | $65.80 | NM |
Frequently Asked Questions
Is vancomycin 25 MG/ML Oral Solution [Firvanq] covered by Medicare Part D?
Yes, vancomycin 25 MG/ML Oral Solution [Firvanq] is covered by 29 Medicare Part D plans (0.6% of all Part D formularies).
What tier is vancomycin 25 MG/ML Oral Solution [Firvanq] on Medicare Part D plans?
vancomycin 25 MG/ML Oral Solution [Firvanq] averages Tier 2.6 across Part D plans, ranging from Tier 1 to Tier 3.
Does vancomycin 25 MG/ML Oral Solution [Firvanq] require prior authorization?
0% of Part D formularies require prior authorization for vancomycin 25 MG/ML Oral Solution [Firvanq]. Step therapy: 0%. Quantity limits: 40%.
How much does Medicare spend on vancomycin 25 MG/ML Oral Solution [Firvanq]?
In 2023, total Medicare Part D spending on vancomycin 25 MG/ML Oral Solution [Firvanq] was $66,162,664, covering 161,077 beneficiaries. The average spend per beneficiary was $410.75.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 1 ML haloperidol decanoate 50 MG/ML Injection T2.6
- 12 HR carbamazepine 100 MG Extended Release Oral Tablet T2.6
- {74 (apixaban 5 MG Oral Tablet [Eliquis]) } Pack [Eliquis 30-Day Starter Pack] T2.6
- apixaban 2.5 MG Oral Tablet [Eliquis] T2.6
- bacitracin 0.5 UNT/MG Ophthalmic Ointment T2.6
- chloroquine phosphate 250 MG Oral Tablet T2.6
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA